Pulmonary delivery particles comprising an active agent
A pulmonary delivery medicament comprises a plurality of particulates, the particulates comprising a structural matrix and a water insoluble and/or crystalline active agent. The particulates have a geometric diameter of 0.5 to 50 μm. The water insoluble active agent can be a fungicide, antibiotic, budesonide. A method of making the medicament comprises forming a liquid feedstock, and forming a feedstock suspension by suspending in the liquid feedstock, the active agent and an excipient capable of forming a structural matrix, such as a phospholipid. The feedstock suspension is spray dried to produce the particulates.
1. An inhaleable powder composition comprising a plurality of particulate microstructures, the particulate microstructures comprising:
(a) a structural matrix comprising phospholipid, wherein the particulate microstructures comprise greater than 10% phospholipid;
(b) an active agent, wherein the particulate microstructures comprise greater than 50% active agent and wherein the active agent comprises an antibiotic;
(c) residual amounts of a blowing agent, wherein the blowing agent comprises a fluorinated compound having a boiling point greater than 80° C., and wherein the residual amounts are 5% w/w or less; and
(d) a mean aerodynamic diameter of less than 5 microns and a mean geometric diameter of less than 5 microns.
2. The inhaleable powder composition of claim 1 wherein the particulate microstructure comprises 1% w/w or less of blowing agent.
3. The inhaleable powder composition of claim 1 wherein the particulate microstructure comprises 3% w/w or less of blowing agent.
4. The inhaleable powder composition of claim 1 wherein the blowing agent comprises perfluorooctylbromide.
5. The inhaleable powder composition of claim 1 wherein the microstructures comprise a bulk density of less than 0.5 g/cm 3 .
6. The inhaleable powder composition of claim 1 wherein the microstructures have a mean porosity of 0.5-80%.
7. The inhaleable powder composition of claim 1 wherein the phospholipid is selected from the group consisting of dilauroylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine, dibehenoylphosphatidylcholine, diarachidoylphosphatidylcholine and combinations thereof.
8. The inhaleable powder composition of claim 1 wherein the structural matrix further comprises calcium.
9. The inhaleable powder composition of claim 1 wherein the powder has a fine particle fraction of from 30-70% by weight.
10. The inhaleable powder composition of claim 7 wherein the structural matrix further comprises calcium.
11. The inhaleable powder composition of claim 1 wherein the antibiotic comprises an aminoglycoside.
12. The inhaleable powder composition of claim 11 wherein the aminoglycoside comprises gentamicin.
13. The inhaleable powder composition of claim 1 wherein the blowing agent has a boiling point greater than 100° C.
14. An inhaleable powder composition comprising a plurality of particulate microstructures, the particulate microstructures comprising:
(a) a structural matrix comprising phospholipid, wherein the particulate microstructures comprise greater than 10% phospholipid;
(b) an active agent, wherein the particulate microstructures comprise greater than 50% active agent and wherein the active agent comprises an antibiotic;
(c) residual amounts of a blowing agent, wherein the blowing agent comprises a fluorinated compound having a boiling point greater than 80° C., and wherein the residual amounts are 5% w/w or less;
(d) residual amounts of a moisture, wherein the residual amounts are less than 6% w/w and wherein the moisture comprises water; and
(e) a mean aerodynamic diameter of less than 5 microns.
15. The inhaleable powder composition of claim 14 wherein the residual amount of moisture is less than 3% w/w.
16. The inhaleable powder composition of claim 14 wherein the blowing agent has a boiling point greater than 100° C. and a mean geometric diameter of less than 5 microns.
17. The inhaleable powder composition of claim 14 wherein the phospholipid is selected from the group consisting of dilauroylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine, dibehenoylphosphatidylcholine, diarachidoylphosphatidylcholine and combinations thereof.
18. The inhaleable powder composition of claim 14 wherein the antibiotic comprises an aminoglycoside.